Pygeum: Clinical Use. Dosage

The most commonly studied product is Tadenan (Laboratoires DEBAT, Garches, France), which is a lipophilic extract standardised to contain 12-13% total sterols.

BENIGN PROSTATIC HYPERTROPHY

A Cochrane systematic review analysed the results of 18 clinical trials that involved a total of 1562 participants. Seventeen studies were double-blinded and the mean treatment duration was 61 ± 21 days (range 30-122 days). Most studies used a standardised extract of P. africanum in doses ranging from 75 to 200 mg/day.

Twelve of the 13 placebo-controlled studies reported a beneficial effect on at least one parameter (overall symptoms, nocturia, peak urine flow, or residual volume), whereas one study found no significant effects. The overall summary effect size indicated a large and statistically significant improvement with P. africanum. More specifically, active treatment increased peak urine flow by 23%, reduced residual urine volume by 24% and physicians were twice as likely to report their patients were experiencing an overall improvement in symptoms when pygeum was being used. The authors report that these findings are similar to other widely used treatment options and that treatment was well tolerated.

It is believed that the phytosterols, pentacyclic triterpenes and ferulic esters found within the extract work synergistically to counteract the structural and biochemical changes associated with BPH.

Pygeum: Other Uses

FERTILITY DISORDERS

Pygeum extract was used experimentally in the treatment of 22 men with reduced fertility and diminished prostatic secretion and proved to have a beneficial effect. Treatment was administered daily over 2 months and was most effective in men who did not have prostatitis.

Pygeum: Dosage Range

ACCORDING TO CLINICAL STUDIES

• BPH: 50-100 mg twice daily of extract standardised to 12-13% total sterols